139 related articles for article (PubMed ID: 8195324)
1. Amplification of N-myc gene and increase of urinary VMA and HVA in patients with neuroblastic tumors.
Akimaru K; Shoji T; Fukunaga Y; Yamamoto M; Ishizaki R; Nomura N
Nihon Ika Daigaku Zasshi; 1994 Apr; 61(2):148-53. PubMed ID: 8195324
[TBL] [Abstract][Full Text] [Related]
2. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
3. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma.
Nishi M; Miyake H; Takeda T; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hirama T; Ishikawa Y; Kudoh T; Azuma H; Takase A
Oncol Rep; 1998; 5(3):631-3. PubMed ID: 9538165
[TBL] [Abstract][Full Text] [Related]
4. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
5. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
7. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
8. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
Tuchman M; Ramnaraine ML; Woods WG; Krivit W
Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
[TBL] [Abstract][Full Text] [Related]
9. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
Lam L; Woollard GA; Teague L; Davidson JS
Ann Clin Biochem; 2017 Mar; 54(2):264-272. PubMed ID: 27235704
[TBL] [Abstract][Full Text] [Related]
11. A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibodies against VMA and HVA.
Yokomori K; Hori T; Tsuchida Y; Kuroda M; Yoshioka M
J Pediatr Surg; 1989 Apr; 24(4):391-4. PubMed ID: 2659761
[TBL] [Abstract][Full Text] [Related]
12. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections.
Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W
Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335
[TBL] [Abstract][Full Text] [Related]
13. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma.
Barco S; Gennai I; Reggiardo G; Galleni B; Barbagallo L; Maffia A; Viscardi E; De Leonardis F; Cecinati V; Sorrentino S; Garaventa A; Conte M; Cangemi G
Clin Biochem; 2014 Jun; 47(9):848-52. PubMed ID: 24769278
[TBL] [Abstract][Full Text] [Related]
14. Development of a new biochemical test to diagnose and monitor neuroblastoma in Vietnam: homovanillic and vanillylmandelic acid by gas chromatography-mass spectrometry.
Tran MT; Baglin J; Tran TT; Hoang KT; Phung LT; Read A; Greaves RF
Clin Biochem; 2014 Feb; 47(3):206-15. PubMed ID: 24296288
[TBL] [Abstract][Full Text] [Related]
15. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
[TBL] [Abstract][Full Text] [Related]
16. Features and outcome of advanced neuroblastoma with distant lymph node metastasis.
Yamada S; Ishii E; Nakagawara A; Akazawa K; Tasaka H; Kajiwara M; Kawakami K; Ueda K
Pediatr Hematol Oncol; 1992; 9(1):49-56. PubMed ID: 1558776
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma.
Tuchman M; Robison LL; Maynard RC; Ramnaraine ML; Krivit W
Clin Biochem; 1985 Jun; 18(3):176-9. PubMed ID: 4039636
[TBL] [Abstract][Full Text] [Related]
18. Serial measurement of urinary VMA and HVA levels from one infant: a study for neuroblastoma mass screening.
Sawada T; Numata K; Hirata S
J Pediatr Surg; 1992 Apr; 27(4):452-5. PubMed ID: 1522454
[TBL] [Abstract][Full Text] [Related]
19. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life.
Kerbl R; Urban C; Starz I; Ambros IM; Strehl S; Kovar H; Gadner H; Ambros PF
Med Pediatr Oncol; 1993; 21(9):625-6. PubMed ID: 8412992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
